Eterna Therapeutics Inc. stock is down -11.02% since 30 days ago. The next earnings date is Mar 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.36% of the previous 32 December’s closed higher than November.
Brooklyn ImmunoTherapeutics, Inc. engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology.